Altimmune said its GLP-1/glucagon agonist pemvidutide reduced drinking in people with moderate-to-severe alcohol use disorder in a Phase 2 trial. In the RECLAIM study, patients received weekly pemvidutide or placebo, with the company reporting separation on drinking outcomes that it characterized as supportive of further development. While the update is mid-stage, it adds to a growing clinical interest in metabolic hormone pathways as potential levers for addiction-related behaviors. The company’s next steps will likely focus on defining effect durability and translating dosing strategy into broader populations. For biotech, the readout strengthens the case for cross-therapeutic-area repurposing of incretin-linked mechanisms into behavioral health endpoints, a category often constrained by limited pharmacologic progress.